Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution

Neuromuscul Disord. 2018 Oct;28(10):865-867. doi: 10.1016/j.nmd.2018.08.004. Epub 2018 Aug 10.

Abstract

Rhabdomyolysis with myoglobinuria is a recognized complication of dystrophinopathies. It can be triggered by infections, exercise or volatile anesthetics. To our knowledge, it has never been reported in boys with Duchenne muscular dystrophy (DMD) after the administration of bisphosphonates. We report two patients with DMD who presented an apparent transient rhabdomyolysis with myoglobinuria after zoledronate administration. Possible mechanisms could involve hypophosphatemia, a known dose-dependent side effect of bisphosphonates, and/or direct myotoxicity of biphosphonates. Physicians and families should be aware of rhabdomyolysis with myoglobinuria as a potential uncommon side effect of bisphosphonates in DMD, in particular of zoledronate.

Keywords: Duchenne muscular dystrophy; bisphosphonates; myoglobinuria; zoledronate.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Bone Density Conservation Agents / adverse effects*
  • Bone Density Conservation Agents / therapeutic use*
  • Humans
  • Male
  • Muscular Dystrophy, Duchenne / complications
  • Muscular Dystrophy, Duchenne / drug therapy*
  • Myoglobinuria / etiology*
  • Zoledronic Acid / adverse effects*
  • Zoledronic Acid / therapeutic use*

Substances

  • Bone Density Conservation Agents
  • Zoledronic Acid